# Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

> **NCT02628613** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 91 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Vinorelbine plus Epirubicin
- **DRUG:** Paclitaxel plus Epirubicin

## Key facts

- **NCT ID:** NCT02628613
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2019-02
- **Final completion:** 2019-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628613, "Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02628613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*